Head to head
Sermorelin / GHRP against CJC-1295 / Ipamorelin
The two standard growth hormone blends. One of them has something the other does not: the class combination of a GHRH with a GHRP has genuine acute human data, where adding a GHRH to GHRP-6 roughly doubled the growth hormone peak in 20 patients. That was a single intravenous diagnostic test, not a nightly protocol, and neither specific vial has ever been studied.
Column A
Sermorelin / GHRPSermorelin combined with GHRP-2 or GHRP-6 (compounding pharmacy growth hormone blend)
The standard compounding pharmacy growth hormone blend, usually sold as 5 mg sermorelin with 5 mg GHRP-2 in one 10 mg vial. This is the only blend on this site where the class combination has genuine human data: adding a GHRH to GHRP-6 roughly doubled the acute growth hormone peak, 54.7 against 25.7 micrograms per litre in 20 patients. That was a single intravenous diagnostic test in a hospital, not a nightly subcutaneous protocol, and the specific vial has never been studied.
Column B
CJC-1295 / IpamorelinCJC-1295 and Ipamorelin blend (GHRH analogue plus ghrelin mimetic)
The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both.
Side by side, on the facts we can check
| Attribute | Sermorelin / GHRP | CJC-1295 / Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not approved as a blend. Sermorelin was previously FDA-approved as Geref and is now supplied compounded; GHRP-2 is approved in Japan as a diagnostic agent only; GHRP-6 is not approved anywhere. | Not approved. Neither component is an approved drug, and the combination has never been submitted or studied. |
| Half-life | Not one number. Both components clear within roughly an hour, the secretagogue somewhat more slowly than the GHRH fragment, and neither has been measured in the presence of the other. | Not one number. The two components clear on completely different timescales, one within a few hours and the other over about a week. |
| Molecular weight | Mixture; sermorelin 3,357.9 Da, GHRP-2 817.0 Da, GHRP-6 873.0 Da | Mixture; CJC-1295 with DAC about 3,647.2 Da, ipamorelin 711.85 Da |
| Mechanism | Sermorelin activates the pituitary GHRH receptor, raising growth hormone pulse amplitude while preserving hypothalamic feedback. GHRP-2 and GHRP-6 activate the growth hormone secretagogue receptor GHS-R1a, a separate receptor cloned in 1996, releasing growth hormone and suppressing somatostatin tone. Because the two receptors are distinct and somatostatin withdrawal amplifies the GHRH signal, the combined response is larger than either alone, and in human testing roughly double. GHRP-6 in particular also raises appetite, cortisol and prolactin, which is why the later, more selective secretagogues were developed. | Two receptors on the same pituitary cell. CJC-1295 activates the GHRH receptor, raising the amplitude of growth hormone pulses; albumin binding through the Drug Affinity Complex extends that signal for days in the DAC version. Ipamorelin activates the growth hormone secretagogue receptor GHS-R1a, the ghrelin receptor, which both releases growth hormone and suppresses somatostatin tone. Combining a GHRH agonist with a GHS-R agonist produces a larger pulse than either alone in human testing, though that testing used GHRH itself with GHRP-6, not this pair. |
| Human studies cited | 5 | 3 |
| Legal status, US | No approved blend; sermorelin is available compounded | Not approved; research use only |
Frequently asked questions
What is the difference between Sermorelin / GHRP and CJC-1295 / Ipamorelin?
Sermorelin / GHRP: The standard compounding pharmacy growth hormone blend, usually sold as 5 mg sermorelin with 5 mg GHRP-2 in one 10 mg vial. This is the only blend on this site where the class combination has genuine human data: adding a GHRH to GHRP-6 roughly doubled the acute growth hormone peak, 54.7 against 25.7 micrograms per litre in 20 patients. That was a single intravenous diagnostic test in a hospital, not a nightly subcutaneous protocol, and the specific vial has never been studied. CJC-1295 / Ipamorelin: The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both.
Which has stronger research evidence, Sermorelin / GHRP or CJC-1295 / Ipamorelin?
This database does not grade compounds. It counts what was run in people: 5 of the 6 studies cited on the Sermorelin / GHRP profile were human work, against 3 of 5 for CJC-1295 / Ipamorelin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Sermorelin / GHRP and CJC-1295 / Ipamorelin FDA-approved?
Sermorelin / GHRP: Not approved as a blend. Sermorelin was previously FDA-approved as Geref and is now supplied compounded; GHRP-2 is approved in Japan as a diagnostic agent only; GHRP-6 is not approved anywhere.. CJC-1295 / Ipamorelin: Not approved. Neither component is an approved drug, and the combination has never been submitted or studied..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.